Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Update

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) was the target of a large increase in short interest in November. As of November 15th, there was short interest totalling 1,310,000 shares, an increase of 6.5% from the October 31st total of 1,230,000 shares. Based on an average daily trading volume, of 683,000 shares, the short-interest ratio is presently 1.9 days. Approximately 4.0% of the shares of the stock are short sold.

Werewolf Therapeutics Trading Down 5.1 %

HOWL opened at $1.86 on Wednesday. Werewolf Therapeutics has a twelve month low of $1.58 and a twelve month high of $8.19. The firm’s 50-day simple moving average is $2.19 and its 200-day simple moving average is $2.57. The company has a quick ratio of 10.10, a current ratio of 10.10 and a debt-to-equity ratio of 0.29.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Werewolf Therapeutics in a research report on Tuesday, November 19th.

Institutional Trading of Werewolf Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Millennium Management LLC raised its stake in shares of Werewolf Therapeutics by 96.4% in the second quarter. Millennium Management LLC now owns 1,110,298 shares of the company’s stock valued at $2,709,000 after acquiring an additional 544,881 shares during the last quarter. Vanguard Group Inc. raised its position in Werewolf Therapeutics by 26.8% in the 1st quarter. Vanguard Group Inc. now owns 1,107,347 shares of the company’s stock valued at $7,176,000 after purchasing an additional 233,909 shares during the last quarter. PFM Health Sciences LP boosted its stake in Werewolf Therapeutics by 4.9% in the third quarter. PFM Health Sciences LP now owns 3,398,747 shares of the company’s stock worth $7,205,000 after purchasing an additional 157,673 shares in the last quarter. Marshall Wace LLP grew its holdings in shares of Werewolf Therapeutics by 410.5% during the second quarter. Marshall Wace LLP now owns 134,184 shares of the company’s stock worth $327,000 after purchasing an additional 107,900 shares during the last quarter. Finally, Renaissance Technologies LLC increased its stake in shares of Werewolf Therapeutics by 103.1% in the second quarter. Renaissance Technologies LLC now owns 171,000 shares of the company’s stock valued at $417,000 after buying an additional 86,800 shares in the last quarter. 64.84% of the stock is owned by institutional investors.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.